Spots Global Cancer Trial Database for Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
Official Title: Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma A Multicenter, Prospective Blinded Study
Study ID: NCT02647112
Conditions
Interventions
Study Description
Brief Summary: Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology.
Detailed Description: Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for reccurrence of bladder cancer.
Keywords
Eligibility
Minimum Age: 22 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tubingen University Medical Center, Tubingen, , Germany
Meir Medical Center, Kfar Saba, , Israel
AMC Medical Center, Amsterdam, , Netherlands
ZGT Medical Center, Hengelo, , Netherlands
Radboud University Medical Center, Nijmegen, , Netherlands
Vall D'Hebron Medical Center, Barcelona, , Spain
Contact Details
Name: Shmulik Adler
Affiliation: Nucleix Ltd.
Role: STUDY_DIRECTOR
Name: Fred Witjes, Prof.
Affiliation: Radboud University Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
